Akebia Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity (Deficit

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'(Deficit)
(dollars in thousands) · Shares · Amount
Balance at December 31, 2023	194,582,539		$2	$1,578,358	$6	$(1,608,950)	$(30,584)
Issuance of common stock, net of issuance costs	13,261,311		—	18,740	—	—	18,740
Proceeds from sale of stock under employee stock purchase plan	92,321		—	70	—	—	70
Exercise of options	280,260		—	141	—	—	141
Stock-based compensation expense	—		—	2,360	—	—	2,360
Restricted stock unit vesting	1,237,718		—	—	—	—	—
Net loss	—		—	—	—	(17,985)	(17,985)
Balance at March 31, 2024	209,454,149		$2	$1,599,669	$6	$(1,626,935)	$(27,258)
Exercise of options	23,892		—	14	—	—	14
Stock-based compensation expense	—		—	2,072	—	—	2,072
Restricted stock unit vesting	451,104		—	—	—	—	—
Net loss	—		—	—	—	(8,582)	(8,582)
Balance at June 30, 2024	209,929,145		$2	$1,601,755	$6	$(1,635,517)	$(33,754)
Issuance of common stock, net of issuance costs	1,242,662		—	1,662	—	—	1,662
Proceeds from sale of stock under employee stock purchase plan	97,411		—	83	—	—	83
Exercise of options	2,312		—	—	—	—	—
Stock-based compensation expense	—		—	1,646	—	—	1,646
Restricted stock unit vesting	270,592		—	—	—	—	—
Net loss	—		—	—	—	(20,039)	(20,039)
Balance at September 30, 2024	211,542,122		$2	$1,605,146	$6	$(1,655,556)	$(50,402)
Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Equity (Deficit)
(dollars in thousands)	Shares	Amount
Balance at December 31, 2024	224,848,992		$2	$1,629,167	$6	$(1,678,360)	$(49,185)
Issuance of common stock, net of issuance costs	34,437,364		—	64,907	—	—	64,907
Proceeds from sale of stock under employee stock purchase plan	93,362		—	78	—	—	78
Exercise of options	604,325		—	482	—	—	482
Stock-based compensation expense	—		—	2,187	—	—	2,187
Restricted stock unit vesting	1,660,547		—	—	—	—	—
Net income	—		—	—	—	6,112	6,112
Balance at March 31, 2025	261,644,590		$2	$1,696,821	$6	$(1,672,248)	$24,581
Issuance of common stock, net of issuance costs	850,000		—	1,542	—	—	1,542
Exercise of options	95,996		—	178	—	—	178
Stock-based compensation expense	—		—	2,676	—	—	2,676
Restricted stock unit vesting	451,246		—	—	—	—	—
Net income	—		—	—	—	247	247
Balance at June 30, 2025	263,041,832		$2	$1,701,217	$6	$(1,672,001)	$29,224
Warrants exercised, cashless	1,408,588		—	7,494	—	—	7,494
Proceeds from sale of stock under employee stock purchase plan	94,060		—	151	—	—	151
Exercise of options	438,300		—	962	—	—	962
Stock-based compensation expense	—		—	3,221	—	—	3,221
Restricted stock unit vesting	243,258		—	—	—	—	—
Net income	—		—	—	—	540	540
Balance at September 30, 2025	265,226,038		$2	$1,713,045	$6	$(1,671,461)	$41,592

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.